THE ROLE OF INTERFERON ALPHA-2b IN REDUCING OF VIRAL LOAD IN HPV INFECTED WOMEN
Main Article Content
Abstract
Human papilloma virus (HPV) is the causal agent, necessary for the development of cervical cancer (CC). The International Agency for Research on Cancer (IARC) has classified 12 HPV types as group 1 carcinogens (oncogenic or high risk): HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59. Persistence HPV is associated with an increased risk of developing cervical squamous epithelial neoplasia (SIL) and СС. There is evidence that cell mediated immune responses of the host, both systemic and local, are important determinants of the course of infection . The use of interferon drugs in complex therapy of HPV infection can lead to reduction of viral load.
The aim – to determine the frequency of different high risk types of HPV and to evaluate the effectiveness of the drug «Viferon» in reducing of viral load in HPV infected women.
Materials and methods. The authors performed a prospective, randomized, placebo uncontrolled study. We have formed 2 groups among 60 women with HPV infection. The main group (n = 30) received rectal suppositories with interferon alfa-2b in dosage of 1000000 IU. In the comparison group (n = 30) treatment was not carried out. High-risk HPV DNA detection and viral load testing was performed by PCR.
Results. Mono-infection was dominated among the patients of both groups the most common was HPV 16 (I – 28,6 %; II – 27,8 %). On the first visit, in group I was 3,5 ± 0,2 Lg (HPV/105 cells), in group II – 3,4 ± 0,3 Lg (p = 0,473). Viral load after 1 month was 1,9 ± 0,3 Lg (HPV/105 cells) and 2,8 ± 0,4 Lg, respectively (p = 0,04). In group I the viral load decreased by 45,5 %, in group II – by 18,3 % (p = 0,01).
Conclusion. Mono-infection was prevalent among HPV infected women HPV 16 is the most frequently detected hrHPV. The use of the drug interferon alfa-2b in the study group, contributed to viral load reduction.Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
World Health Organization: Human papillomavirus laboratory manual. First edition. 2009. [Электронный ресурс]. – URL: http://www.who.int/immunization/hpv/learn/hpv_laboratory_manual__who_ivb_2009_2010.pdf (дата обращения: 02.12.2016)
Castellsagué X, Paavonen J, Jaisamram U, Wheeler CM, Skinner SR. Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized controlled PATRICIA trial. BMC Infectious Diseases. 2014; (14): 551
Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O'Reilly S, Kiviat NB, Koutsky LA. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol. Biomarkers Prev. 2011; 20(4): 699-707
Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am. J. Epidemiol. 2008; 168(2): 123-137
Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM. Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study. PLoS One. 2013; 8(12): е79260. DOI: 10.1371/annotation/cea59317-929c-464a-b3f7-e095248f229a
Ekalaksananan T, Malat P, Pientong C, Kongyingyoes B, Chumworathayi B, Kleebkaow P. Local cervical immunity in women with low-grade squamous intraepithelial lesions and immune responses after abrasion. Asian Pac. J. Cancer Prev. 2014; 15(10): 4197-4201
Frazer I. Correlating immunity with protection for HPV infection. J. Infect. 2007; 11(2): 10-16
Amador-Molina A, Hernández-Valencia JF, Lamoyi E, Contreras-Paredes A, Lizano M. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses. 2013; 5(11): 2624-2642
Podzolkova NM, Rogovskaya SI, Fadeev IE, Damirov MM, Sozayeva LG, Osadchev VB. Papillomavirus infection in obstetrics and gynecology: a guide for physicians. M.: GEOTAR-Media, 2012. 64 p. Russian (Подзолкова Н.М., Роговская С.И., Фадеев И.Е., Дамиров М.М., Созаева Л.Г., Осадчев В.Б. Папилломавирусная инфекция в акушерстве и гинекологии: руководство для врачей. М.: ГЭОТАР-Медиа, 2012. 64 с.)
Semenov DM. Immunopathogenetic changes at the women infected of the human papilloma virus. Immunopathology, allergology, infectology. 2016; (2): 67-73. Russian (Семенов Д.М. Иммунологические изменения у женщин, инфицированных вирусом папилломы человека //Иммунопатология, Аллергология, Инфектология. 2016. № 2. С. 67-73)
Kuzmina IU, Kalinovskaya OI, Kuzmina OA, Fedorchenko VO. Modern aspects of complex therapy to be recurrent papillomatous viral infection. International Medical Journal. 2014; (1): 51-55. Russian (Кузьмина И.Ю., Калиновская О.И., Кузьмина О.А., Федорченко В.А. Современные аспекты комплексной терапии рецидивирующей папилломавирусной инфекции //Международный медицинский журнал. 2014. № 1. С. 51-55
Grenkova YM, Safronova MM. Comprehensive examination and treatment of patients with benign cervical diseases of inflammatory genesis. AG-info. 2010; (1): 10-14. Russian (Гренкова Ю.М., Сафронова М.М. Комплексное обследование и лечение пациенток с доброкачественными заболеваниями шейки матки воспалительного генеза //АГ-инфо. 2010. № 1. С. 10-14)
Bagramova GE, Gureyeva MA, Khlebnikova AN, Molochkov AV, Kucherov VA, Stovbun SV, Safronov DY, Bagayeva MI. Immunotropic therapy in the multimodality treatment of genital papillomavirus infection. The Russian Journal of Dermatology and Venereology. 2012; (4): 58-61. Russian (Баграмова Г.Э., Гуреева М.А., Хлебникова А.Н., Молочков А.В., Кучеров В.А., Стовбун С.В., Сафронов Д.Ю., Багаева М.И. Комплексное лечение генитальной папилломавирусной инфекции //Клиническая дерматология и венерология. 2012. № 4. С. 58-61)
Misson DR, Abdalla DR, Borges AM, Shimba DS, Adad SJ, Michelin MA, Murta EF. Cytokine serum levels in patients with cervical intraepithelial neoplasia grade II-III treated with intralesional interferon-α 2b. Tumori. 2011; 97(5): 578-584
Prilepskaya VN, Rogovskaya SI, Bebneva TN, Mezhevitinova EA, Petrunin DD. The use of interferon in the treatment of low-grade squamous intraepithelial lesions. AG-info. 2008; (3): 15-21. Russian (Прилепская В.Н., Роговская С.И., Бебнева Т.Н., Межевитинова Е.А., Петрунин Д.Д. Применение препаратов интерферона при лечении плоскоклеточных интраэпителиальных поражений шейки матки низкой степени //АГ-инфо. 2008. № 3. С. 15-21)
Belyakovsky VN, Al-Jahiri OV, Al-Jahiri AK. Role of interferonotherapy in treatment of papillomavirus infection. Health and Environment Issues. 2010; 1(23): 139-142. Russian (Беляковский В.Н., Аль-Яхири О.В., Аль-Яхири А.К. Способ элиминационной эндовагинальной интерферонотерапии в лечении папилломавирусной инфекции //Проблемы здоровья и экологии. 2010. № 1(23). С. 139-142)
Rogovskaya SI. Human papillomavirus infection in women and cervical pathology. M.: GEOTAR-Media, 2005. 144 p. Russian (Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки. М.: ГОЭТАР-Медиа, 2005. 144 с.)
Andreeva TS, Malyshkina AI, Sotnikova NYu. Systemic and local immunity status in women with background cervical diseases and papillomavirus infection: 2-alpha-interferon influence. Bulletin of the Ivanovo Medical Academy. 2012; 4(17): 16-19. Russian (Андреева Т.С., Малышкина А.И., Сотникова Н.Ю. Влияние препарата интерферона 2α на состояние системного и местного иммунитета у женщин с фоновыми заболеваниями шейки матки и папилломавирусной инфекцией //Вестник Ивановской медицинской академии. 2012. № 4(17). С. 16-19)
Artymuk NV, Marochko KV. Efficiency of human papillomavirus detection with a vaginal discharge self-collection device. Obstetrics and Gynecology. 2016; (3): 85-91. Russian (Артымук Н.В., Марочко К.В. Эффективность выявления вируса папилломы человека при помощи устройства для самостоятельного забора вагинального отделяемого //Акушерство и гинекология. 2016. № 3. С. 85-91)
Eliseeva MYu, Manukhin IB, Mynbaev OA, Zvereva NS, Mishutina AA, Tcarev VN. Antiviral effect of isoprinosine in HPV-associated diseases. Obstetrics and Gynecology. 2012; (2): 107-114. Russian (Елисеева М.Ю., Манухин И.Б., Мынбаев О.А., Зверева Н.С., Мишутина А.А., Царев В.Н. Противовирусный эффект инозина пранобекса при ВПЧ-ассоциированных заболеваниях //Акушерство и гинекология. 2012. № 2. С. 107-114)